✦ LIBER ✦

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

✍ Scribed by Hudis, Clifford; Swanton, Charles; Janjigian, Yelena Y; Lee, Ray; Sutherland, Stephanie; Lehman, Robert; Chandarlapaty, Sarat; Hamilton, Nicola; Gajria, Devika; Knowles, James; Shah, Jigna; Shannon, Keith; Tetteh, Ernestina; Sullivan, Daniel M; Moreno, Carolina; Yan, Li; Han, Hyo

Book ID: 121591620
Publisher: BioMed Central
Year: 2013
Tongue: English
Weight: 622 KB
Volume: 15
Category: Article
ISSN: 1465-5411
DOI: 10.1186/bcr3577

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 1 trial of the oral AKT inhibitor

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

✍ L Rhoda Molife,Li Yan,Joanna Vitfell-Rasmussen… 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 389 KB

1202 ORAL A Phase I Study of the Potent

1202 ORAL A Phase I Study of the Potent AKT Inhibitor MK-2206 in Combination With Carboplatin and Paclitaxel, Docetaxel or Erlotinib in Patients With Advanced Solid Tumours

✍ L.R. Molife; S. Minton; J. Vitfell-Pedersen; E. Chen; D. Sullivan; L. Yan; A.M. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 64 KB

Phase I, dose-finding study of AZD8931,

Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors

✍ Tjulandin, S.; Moiseyenko, V.; Semiglazov, V.; Manikhas, G.; Learoyd, M.; Saunde 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 313 KB

A phase 1 study of TRC102, an inhibitor

A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors

✍ Gordon, Michael S.; Rosen, Lee S.; Mendelson, David; Ramanathan, Ramesh K.; Gold 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 224 KB

Phase I study evaluating the combination

Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528

✍ Gadgeel, Shirish M.; Lew, Danika L.; Synold, Timothy W.; LoRusso, Patricia; Chun 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 400 KB

A phase 1 and dose-finding study of LY25

A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors

✍ Wakui, Hiroshi; Yamamoto, Noboru; Kitazono, Satoru; Mizugaki, Hidenori; Nakamich 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 366 KB